Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Tamara Ghanem

- PMLiVE

OPEN Health and fusion announce partnership to deliver AI-powered healthcare communications

OPEN Health, a pre-eminent global provider of scientific communications, HEOR and market access, patient engagement, and consulting, today announced a partnership with fusion, an innovative artificial intelligence (AI) and machine...

OPEN Health

- PMLiVE

Takeda’s Fruzaqla approved by EC to treat metastatic colorectal cancer in adults

Approximately 538,000 new cases of colorectal cancer were diagnosed in Europe in 2022

- PMLiVE

Bristol Myers Squibb’s Krazati granted FDA accelerated approval in colorectal cancer

More than 106,000 new cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

Study reveals single copy of protective genetic variant delays early Alzheimer’s onset

Approximately 900,000 people in the UK are affected by dementia and Alzheimer’s is the most common form

- PMLiVE

Gilead shares positive phase 3 results for twice-yearly HIV PrEP drug in women

Lenacapavir demonstrated 100% efficacy in protecting more than 2,000 women against the infection

- PMLiVE

MIT researchers develop new algorithmic framework to identify molecules for drug discovery

SPARROW balances time and cost when optimising molecular candidates to streamline

- PMLiVE

Beyond volume metrics: towards meaningful impact measurement for digital HCP engagement

By Matthew Hellyer

- PMLiVE

Eyes on the horizon: six (and a half) predictions for the future of healthcare communications

By Zoë van Helmond and Leyna Prince

Amiculum

- PMLiVE

FDA expands indication for Sarepta’s Duchenne muscular dystrophy gene therapy Elevidys

The neuromuscular condition is estimated to affect one in every 3,500 male births worldwide

- PMLiVE

The Communiqué Awards announces PAPYRUS as 2024 charity partner

PAPYRUS Prevention of Young Suicide aims to shatter the stigma that still surrounds suicide

- PMLiVE

Sobi receives EC marketing authorisation for Altuvoct in haemophilia A

The rare bleeding disorder affects approximately one in every 5,000 male births annually

- PMLiVE

J&J’s subcutaneous Tremfya shows promise in phase 3 Crohn’s disease study

Inflammatory bowel disease affects approximately four million people in Europe

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links